64 related articles for article (PubMed ID: 23623865)
1. A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. military recruits.
Kuschner RA; Russell KL; Abuja M; Bauer KM; Faix DJ; Hait H; Henrick J; Jacobs M; Liss A; Lynch JA; Liu Q; Lyons AG; Malik M; Moon JE; Stubbs J; Sun W; Tang D; Towle AC; Walsh DS; Wilkerson D;
Vaccine; 2013 Jun; 31(28):2963-71. PubMed ID: 23623865
[TBL] [Abstract][Full Text] [Related]
2. Vaccine-preventable adenoviral respiratory illness in US military recruits, 1999-2004.
Russell KL; Hawksworth AW; Ryan MA; Strickler J; Irvine M; Hansen CJ; Gray GC; Gaydos JC
Vaccine; 2006 Apr; 24(15):2835-42. PubMed ID: 16480793
[TBL] [Abstract][Full Text] [Related]
3. Strain variation in adenovirus serotypes 4 and 7a causing acute respiratory disease.
Crawford-Miksza LK; Nang RN; Schnurr DP
J Clin Microbiol; 1999 Apr; 37(4):1107-12. PubMed ID: 10074533
[TBL] [Abstract][Full Text] [Related]
4. The role of adenovirus in respiratory tract infections.
Kunz AN; Ottolini M
Curr Infect Dis Rep; 2010 Mar; 12(2):81-7. PubMed ID: 21308503
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of Mucosal Immunogenicity of Viral Vectored Vaccines by the NKT Cell Agonist Alpha-Galactosylceramide as Adjuvant.
Singh S; Nehete PN; Yang G; He H; Nehete B; Hanley PW; Barry MA; Sastry KJ
Vaccines (Basel); 2014 Oct; 2(4):686-706. PubMed ID: 25553254
[TBL] [Abstract][Full Text] [Related]
6. Characterization of nephropathogenic infectious bronchitis virus DMV/1639/11 recovered from Delmarva broiler chickens in 2011.
Gelb J; Ladman BS; Pope CR; Ruano JM; Brannick EM; Bautista DA; Coughlin CM; Preskenis LA
Avian Dis; 2013 Mar; 57(1):65-70. PubMed ID: 23678731
[TBL] [Abstract][Full Text] [Related]
7. Adverse events following adenovirus type 4 and type 7 vaccine, live, oral in the Vaccine Adverse Event Reporting System (VAERS), United States, October 2011-July 2018.
McNeil MM; Paradowska-Stankiewicz I; Miller ER; Marquez PL; Seshadri S; Collins LC; Cano MV
Vaccine; 2019 Oct; 37(44):6760-6767. PubMed ID: 31548014
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus: Epidemiology, Global Spread of Novel Serotypes, and Advances in Treatment and Prevention.
Lynch JP; Kajon AE
Semin Respir Crit Care Med; 2016 Aug; 37(4):586-602. PubMed ID: 27486739
[TBL] [Abstract][Full Text] [Related]
9. Live Oral Adenovirus Type 4 and Type 7 Vaccine Induces Durable Antibody Response.
Collins ND; Adhikari A; Yang Y; Kuschner RA; Karasavvas N; Binn LN; Walls SD; Graf PCF; Myers CA; Jarman RG; Hang J
Vaccines (Basel); 2020 Jul; 8(3):. PubMed ID: 32718082
[TBL] [Abstract][Full Text] [Related]
10. Safety evaluation of adenovirus type 4 and type 7 vaccine live, oral in military recruits.
Choudhry A; Mathena J; Albano JD; Yacovone M; Collins L
Vaccine; 2016 Aug; 34(38):4558-4564. PubMed ID: 27475474
[TBL] [Abstract][Full Text] [Related]
11. Disease Burden and Inpatient Management of Children with Acute Respiratory Viral Infections during the Pre-COVID Era in Germany: A Cost-of-Illness Study.
Alchikh M; Conrad TOF; Obermeier PE; Ma X; Schweiger B; Opota O; Rath BA
Viruses; 2024 Mar; 16(4):. PubMed ID: 38675850
[TBL] [Abstract][Full Text] [Related]
12. A recombinant virus-like particle vaccine against adenovirus-7 induces a potent humoral response.
Mazboudi R; Mulhall Maasz H; Resch MD; Wen K; Gottlieb P; Alimova A; Khayat R; Collins ND; Kuschner RA; Galarza JM
NPJ Vaccines; 2023 Oct; 8(1):155. PubMed ID: 37821505
[TBL] [Abstract][Full Text] [Related]
13. Differential Genome Replication of a Unique Single-Amino-Acid Mutation in the Adenovirus-4 Component of the Live Oral Adenovirus Type 4 and Type 7 Vaccine.
Collins ND; Beaty S; Wallace E; Li Y; Sanborn M; Yang Y; Adhikari A; Shabram P; Warfield K; Karasavvas N; Kuschner RA; Hang J
Vaccines (Basel); 2023 Jun; 11(7):. PubMed ID: 37514960
[TBL] [Abstract][Full Text] [Related]
14. A Phase 1 Two-Arm, Randomized, Double-Blind, Active-Controlled Study of Live, Oral Plasmid-Derived Adenovirus Type 4 and Type 7 Vaccines in Seronegative Adults.
Beaty S; Collins N; Karasavvas N; Kuschner R; Hang J; Adhikari A; Maljkovic Berry I; Fung C; Walls S; Betancourt E; Mendy J; Lock M; Gierman E; Bennett S; Shabram P; Warfield K
Vaccines (Basel); 2023 Jun; 11(6):. PubMed ID: 37376480
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Adenovirus Vaccine Safety Surveillance in Military Setting, United States.
Iskander J; Blanchet S; Springer C; Rockwell P; Thomas D; Pillai S
Emerg Infect Dis; 2023 Jun; 29(6):1283-1285. PubMed ID: 37209695
[TBL] [Abstract][Full Text] [Related]
16. A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health.
Biselli R; Nisini R; Lista F; Autore A; Lastilla M; De Lorenzo G; Peragallo MS; Stroffolini T; D'Amelio R
Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009598
[TBL] [Abstract][Full Text] [Related]
17. Immunity to enteric viruses.
Lockhart A; Mucida D; Parsa R
Immunity; 2022 May; 55(5):800-818. PubMed ID: 35545029
[TBL] [Abstract][Full Text] [Related]
18. Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence.
Focosi D; Maggi F; Casadevall A
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215783
[TBL] [Abstract][Full Text] [Related]
19. Adenovirus-based vaccines-a platform for pandemic preparedness against emerging viral pathogens.
Coughlan L; Kremer EJ; Shayakhmetov DM
Mol Ther; 2022 May; 30(5):1822-1849. PubMed ID: 35092844
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
